Nirog Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 16-07-2024
- Paid Up Capital ₹ 0.82 M
as on 16-07-2024
- Company Age 29 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.28 Cr
as on 16-07-2024
- Revenue 12.55%
(FY 2023)
- Profit -3.48%
(FY 2023)
- Ebitda 11.47%
(FY 2023)
- Net Worth 10.28%
(FY 2023)
- Total Assets 19.06%
(FY 2023)
About Nirog Pharma
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.82 M.
The company currently has active open charges totaling ₹4.28 Cr.
Anil Jain, Manju Jain, Himanshu Jain, and One other member serve as directors at the Company.
- CIN/LLPIN
U74899DL1995PTC064914
- Company No.
064914
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Feb 1995
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Nirog Pharma Private Limited offer?
Nirog Pharma Private Limited offers a wide range of products and services, including Ayurvedic,Herbal Products & Medicine, Ayurvedic Medicine, Ayurvedic Digestive Medicine, Digestive Herbal Capsule & Tablet, Ayurvedic Kidney Medicine, Ayurvedic Digestive Powder, Herbal Piles Medicine.
Who are the key members and board of directors at Nirog Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Priyanshu Jain  | Director | 02-Jan-2017 | Current |
| Himanshu Jain | Director | 01-Apr-2004 | Current |
| Anil Jain | Director | 01-Feb-1995 | Current |
| Manju Jain | Director | 05-Jul-1996 | Current |
Financial Performance of Nirog Pharma.
Nirog Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 12.55% increase. The company also saw a slight decrease in profitability, with a 3.48% decrease in profit. The company's net worth Soared by an impressive increase of 10.28%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nirog Pharma?
In 2023, Nirog Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 10 Jan 2020 | ₹2.31 Cr | Open |
Others Creation Date: 29 Nov 2017 | ₹0.50 M | Open |
Others Creation Date: 04 Jul 2013 | ₹7.90 M | Open |
How Many Employees Work at Nirog Pharma?
Nirog Pharma has a workforce of 11 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nirog Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nirog Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
